You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》里昂升復星醫藥(02196.HK)評級至「跑贏大市」 目標價升至24.09元
阿思達克 02-26 16:28
里昂發表研究報告,指復星醫藥(02196.HK)旗下合營復星凱特的CAR-T細胞治療產品FKC876(益基利侖賽注射液)正式獲得國家藥品監督管理局藥品上市註冊審評受理。該行認為,產品會在明年推出市面,雖然這對2021至2022財年的財務影響有限,但料會成為其股價催化劑。該藥主要用於復發難治性成人大B細胞淋巴瘤的治療。 里昂將復星醫藥的目標價由原來的23.53元上調至24.09元,並將其投資評級由原來的「跑輸大市」調高至「跑贏大市」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account